

Psycho-social intervention for people with HIV

Submission date 04/07/2024	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 12/07/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 12/08/2024	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English Summary

Background and study aims

HIV is now a treatable chronic condition with near-normal life expectancy, often requiring only annual specialist monitoring. However, a unique and interlinked set of adverse factors including high levels of depression, stigma and socioeconomic disadvantage impact on wellbeing and use of specialist services. A new model of care could better address these issues while being cost-saving or cost-neutral for the NHS. The NHS Long Term Plan has an increased emphasis on personalised care to improve health and wellbeing and reduce reliance on clinical services. However, evidence lags behind policy, with significant methodological shortcomings in existing studies, and no UK studies in People Living with HIV (PLWH).

This study aims to evaluate the effectiveness and cost-effectiveness of a health and wellbeing coaching intervention designed as part of the wider NICHE programme. A process evaluation sub-study will investigate factors promoting or inhibiting the uptake of the intervention.

Who can participate?

People living with HIV (PLWH) aged 18 years and over, who are attending an HIV clinic at a recruiting centre.

What does the study involve?

Participants will be randomly allocated to either health and wellbeing coaching + standard care or standard care alone. Participants will complete questionnaires at the start of the study and after 6 and 12 months. Some of the participants will be asked to complete additional study questionnaires at the start of the study and after 12 months to provide information on changes over time in the measures of health and wellbeing, and how frequently PLWH should be re-assessed for psychosocial needs. This will help to inform how clinic-wide psychosocial assessment is implemented into routine care.

What are the possible risks and benefits of taking part?

It is hoped that the intervention and the results of the trial will help improve health and wellbeing among people living with HIV. The trial intervention involves health and wellbeing coaching. There is no specific risk involved. Participants will be asked to complete questionnaires which may be time-consuming, but this can be done online.

Where is the study run from?

1. University College London (UK)

2. University of Birmingham (UK)
3. Birmingham Clinic Trials Unit (UK)

When is the study starting and how long is it expected to run for?
June 2021 to December 2026

Who is funding the study?
National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?
Sphere trial office at BCTU, sphere@trials.bham.ac.uk

Study website

<http://www.birmingham.ac.uk/sphere>

Contact information

Type(s)

Principal Investigator

Contact name

Prof Alison Rodger

ORCID ID

<http://orcid.org/0000-0001-8817-4651>

Contact details

Research Department of Infection and Population Health
University College London
Rowland Hill Street
London
United Kingdom
NW3 2PF

-
Alison.Rodger@ucl.ac.uk

Type(s)

Public

Contact name

Ms Suzanne Lockyer

Contact details

Trial Manager
Birmingham Clinical Trials Unit
Public Health Building
University of Birmingham
Birmingham
United Kingdom

B15 2TT

-

sphere@trials.bham.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

337571

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CPMS 62794, IRAS 337571, NIHR202038

Study information

Scientific Title

Psycho-social intervention for people with HIV (SPHERE) - evidence from a randomised evaluation

Acronym

SPHERE

Study hypothesis

The null hypothesis is that there is no difference in change in PO-11 score where an individual will be counted as a 'success' if there is a reduction of 40% or more in their score from their baseline value score between the intervention groups. The alternative hypothesis is that there is a difference between the groups.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 08/07/2024, London - Fulham Research Ethics Committee (postal address: not available; +44 (0)207 104 8084; Fulham.rec@hra.nhs.uk), ref: 24/LO/0449

Study design

Randomized; Both; Design type: Process of Care, Education or Self-Management, Psychological & Behavioural, Complex Intervention, Cohort study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Condition

HIV

Interventions

The SPHERE intervention will focus on improving mental health and emotional wellbeing, reducing social isolation and stigma, facilitating support with socioeconomic issues and improving health literacy. Eight health and wellbeing coaching sessions (including the initial assessment) will be offered with the aim that they be delivered within a 3-month period.

The HWC will work collaboratively with the participant to identify ways to improve physical /mental health and ameliorate any major social stressors and prioritise the main problem areas. The intervention will use a range of cognitive-behavioural change and problem-solving techniques. Healthcare workers from NHS HIV clinical services participating in the trial will be trained to deliver the SPHERE intervention.

Participants will be randomised in a 1:1 ratio to either health and wellbeing coaching + standard care or standard care alone. Participants will complete questionnaires at baseline, 6 months and 12 months.

In addition there will be an observational cohort which will include participants who scored less than 16 on the PO-11 tool. Participants will be asked to complete the study questionnaires at baseline and 12 months. This will provide information on changes over time in the measures of health and wellbeing, and how frequently PLWH should be re-assessed for psychosocial needs. This will help to inform how clinic-wide psychosocial assessment is implemented into routine care.

Intervention Type

Behavioural

Primary outcome measure

A binary health and wellbeing measure based on the change in PO-11 score where an individual will be counted as a 'success' if there is a reduction of 40% or more in their score from their baseline value. This will be assessed at 6 months post-randomisation.

PO-11 is comprised of 11 questions, each with a 5-point Likert response scale scoring from 0 (best response) to 4 (worst response). The total score will be 0-44 where a higher score indicates a higher burden of symptoms and concerns.

Secondary outcome measures

Clinical:

1. Health and wellbeing measured by the above binary measure based on the PO-11 score as defined for the primary outcome, assessed at 12 months

2. Health and wellbeing measured using the Positive Outcomes (full version) score at 6 and 12 months
3. Depressive symptoms measured using the Patient Health Questionnaire (PHQ-9) at 6 and 12 months (total score and ≥ 10)
4. Viral load (VL) suppression (≤ 40 c/ml [copies/millilitre]) measured using blood test over 12 months
5. Anxiety symptoms measured using the General Anxiety Disorder-7 questionnaire (GAD-7) (score total score and ≥ 10) at 6 and 12 months
6. Self-stigma measured using the relevant Positive Voices questionnaire section at 6 and 12 months
7. Social support measured using a modified version of the Duke-UNC Functional Social Support Questionnaire (FSSQ) measured at 6 and 12 months
8. Resilience measured using the Resilience Scale (RS14) at 6 and 12 months
9. Smoking status self-reported on the participant-completed questionnaires (current smoker, ex-smoker, non-smoker) at 6 and 12 months
10. Alcohol use measured using the Alcohol Use Disorders Identification Test Consumption (AUDIT-C) at 6 and 12 months
11. Recreational drug use in the past 3 months measured using the relevant Positive Voices questionnaire sections at 6 and 12 months
12. Physical activity measured using the modified General Practice Physical Activity Questionnaire (GPPAQ) at 6 and 12 months
13. Self-efficacy measured using the Coping Self-Efficacy Scale (CSES) Short Form at 6 and 12 months

Cost-effectiveness:

1. Health-related quality of life measured using the EuroQol EQ-5D-5L score at 6 and 12 months
2. Health care, social care and welfare utilisation self-reported at 6 and 12 months

Observational cohort:

Participants taking part in the observational study will receive treatment as usual but will complete all baseline assessments and then be re-assessed for unmet needs at 12 months after baseline. The same outcome measures will be collected as for the RCT participants.

Overall study start date

01/06/2021

Overall study end date

01/12/2026

Eligibility

Participant inclusion criteria

1. HIV positive and attending a specialist HIV clinic
2. Aged 18 years or over
3. Able to give valid informed consent for study participation
4. Willing and able to participate in the study and be available for the duration of follow-up

For randomisation only:

5. Scoring ≥ 16 on the HIV Positive Outcomes-11 PROM (PO-11) tool

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned Sample Size: 966; UK Sample Size: 966

Participant exclusion criteria

For RCT only:

1. Active major mental illness (i.e. psychosis or bipolar disorder or active suicidality)
2. Within the first 12 weeks of receiving a new psychotherapy intervention

Recruitment start date

19/08/2024

Recruitment end date

01/08/2025

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Royal London Hospital

Whitechapel Rd

London

United Kingdom

E1 1FR

Study participating centre

Kings College Hospital

Mapother House

De Crespigny Park

Denmark Hill

London

United Kingdom

SE5 8AB

Study participating centre
Chelsea & Westminster Hospital
369 Fulham Road
London
United Kingdom
SW10 9NH

Study participating centre
The Hathersage Centre
280 Upper Brook Street
Manchester
United Kingdom
M13 0FH

Study participating centre
Southmead Hospital
Southmead Road
Westbury-on-trym
Bristol
United Kingdom
BS10 5NB

Study participating centre
Royal Hallamshire Hospital
Glossop Road
Sheffield
United Kingdom
S10 2JF

Study participating centre
Royal Sussex County Hospital
Eastern Road
Brighton
United Kingdom
BN2 5BE

Sponsor information

Organisation

University of Birmingham

Sponsor details

Research Strategy and Services Division
Birmingham Research Park
97 Vincent Drive
Birmingham
England
United Kingdom
B15 2TT
+44 (0)7814650003
researchgovernance@contacts.bham.ac.uk

Sponsor type

University/education

Website

<http://www.birmingham.ac.uk/index.aspx>

ROR

<https://ror.org/03angcq70>

Funder(s)

Funder type

Government

Funder Name

NIHR Central Commissioning Facility (CCF); Grant Codes: NIHR202038

Results and Publications

Publication and dissemination plan

The researchers plan to publish the results of the trial in a high-impact peer-reviewed journal approximately 1 year after the end of the study

Intention to publish date

01/12/2027

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study have not been finalised and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Study website			12/07/2024	No	No
Study website			12/07/2024	No	No